Dave Ritchie
BrainChild Bio Raises $116M Series A on Sept. 8 to Fund Phase 2 B7-H3 CAR T Trial for DIPG
BrainChild Bio raised $116 million in a Series A on Sept. 8 to fund a registrational Phase 2 trial of BCB-276, a B7-H3 CAR T therapy delivered directly into cerebrospinal fluid for DIPG, and to advance a triple-antigen glioblastoma program. The Seattle Children’s spinout aims to bypass the blood-brain barrier with intrathecal delivery after promising early survival signals.
Levanta raises $22M Series B led by Volition Capital to scale creator-to-retailer sales across Amazon, Walmart and Shopify
Seattle startup Levanta raised $22 million in Series B funding led by Volition Capital to expand its creator-to-retailer platform that tracks and drives sales across Amazon, Walmart and Shopify; the company has 90,000 vetted creators, 80% YoY revenue growth in 2026, and has been profitable or near break-even since launch. Levanta automates product seeding, commission tracking and payments to connect creators with sellers and will use the funding to enter additional retail marketplaces.
